By Julien Salaberry
Feb 24, 2015
The Biotechnology Industry Organization (BIO) has released a lengthy white paper on the past decade of VC funding for the biotech sector. Its headline finding is that venture funding for biotech R&D fell by 21% between the five-year period before the financial crisis (2004-2008) and the subsequent five years (2009-2013).
More interesting, however, is where the big funding cuts are occurring. Namely, in areas of the largest medical need. For example funding for novel drug R&D in:
Diabetes fell by 81% between those five-year periods
CNS fell by 56%
GI by 49%
Respiratory by 41%
CV by 33%
On the flip side, funding for rare diseases increased.
Source: Term Sheet, Biotechnology Industry Organisation
https://www.linkedin.com/pulse/significant-drop-chronic-disease-drug-rd-funding-julien-de-salaberry
Our view is that people cannot rely on medication alone and must instead take a holistic look at their lifestyle as early as possible and make necessary changes to live healthier and better lives to the extent possible
